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Abstract: Prostate cancer (PCa) is the most commonly diagnosed cancer as well as the greatest
source of cancer-related mortality in males of African ancestry (MoAA). Interestingly, this has
been shown to be associated with single nucleotide polymorphisms around regions 2 and 3 of
the 8q24 human chromosomal region. The non-protein coding gene locus Plasmacytoma Variant
Translocation 1 (PVT1) is located at 8q24 and is overexpressed in PCa and, therefore, is also a
candidate biomarker to explain the well-known disparity in this group. PVT1 has at least 12 exons
that make separate transcripts which may have different functions, all of which are at present
unknown in PCa. Our aim was to determine if any PVT1 transcripts play a role in aggressiveness
and racial disparity in PCa. We used a panel of seven PCa cell lines including three derived
from MoAA. Ribonucleic acid extraction, complementary deoxyribonucleic acid synthesis, and
quantitative polymerase chain reaction (qPCR) were performed to evaluate expression of all 12 PVT1
exons. Each qPCR was performed in quadruplicates. At least four separate qPCR experiments were
performed. Expression of PVT1 exons was inconsistent except for exon 9. There was no significant
difference in exon 9 expression between cell lines derived from Caucasian males (CM), and an
indolent cell line derived from MoAA. However, exon 9 expression in the aggressive MDA PCa
2b and E006AA-hT cell lines derived from MoAA was significantly higher than in other cell lines.
Consequently, we observed differential expression of exon 9 of PVT1 in a manner that suggests that
PVT1 exon 9 may be associated with aggressive PCa in MoAA.
Keywords: PVT1 exon 9; prostate cancer; disparity; biomarker; males of African ancestry
1. Introduction
Prostate cancer (PCa) is the most common non-cutaneous cancer and the second leading cause
of cancer-related death for men in the U.S. It is estimated that, in 2015, approximately 220,800 new
cases of PCa will be diagnosed and 27,540 deaths will result from PCa [1]. African Americans have
the highest incidence of PCa in the world, with an annual average of 229 per 100,000 men for the
period of 2006–2010, which represents about two-fold more than Caucasian Americans [2]. PCa is
also the leading cancer in terms of incidence and mortality in men from Africa and the Caribbean [3].
Consequently, African ancestry is a very important risk factor.
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PCa is a heterogeneous disease, with multiple risks factors. The specific reasons for poor
outcomes from PCa in males of African ancestry (MoAA) when compared to Caucasian males (CM)
are not understood. However, it is widely believed that the causes of PCa disparities are complex and
multifaceted. Two potential reasons are frequently proposed to explain this profound disparity in
PCa: (1) MoAA present more often than CM with advanced incurable PCa due to more limited access
to health care [4–6]; (2) PCa is biologically more aggressive in MoAA than CM, and can be attributed
to environmental and/or genetic risk factors.
The 8q24 human chromosomal region is one of the most important susceptibility genetic
loci for PCa. Several studies have identified single nucleotide polymorphisms (SNPs) located in
chromosome 8q24 as susceptibility markers for PCa [7–12]. The 8q24 chromosomal region has only
one protein-coding gene, the well-known MYC oncogene implicated in different cancers, including
PCa. However, it also has a number of non-protein coding genes (such as PVT1) whose functional
roles have not been thoroughly investigated yet [13].
In recent years, non-protein coding RNAs (ncRNAs) have received special attention because they
have been identified in many studies as being important in cancer biology. Substantial progress has
been made in understanding the role of small non-coding RNAs such as microRNAs (miRNAs) in
the development and progression of cancers [14,15]. However, studying the role of long non-coding
RNAs (lncRNAs) in cancers appears to be more complicated. LncRNAs are defined as endogenous
cellular RNAs that have a size of more than 200 nucleotides, and that do not possess an extended
open reading frame [16–19].
Plasmacytoma variant translocation 1 (PVT1) is one of the transcribed lncRNAs located at the
8q24 PCa susceptibility locus (Figure 1). The PVT1 gene locus expresses several alternatively spliced
non-protein coding transcripts [20–22] and it also encodes a cluster of microRNAs [23]. However,
no specific functional role for any of these transcripts has been identified [9,24]. PVT1 is located
downstream of MYC. It has a size of over 300 kb and, since its discovery in the mid-80s [25,26],
it has been proven to play an important role in cancer. The upregulation of PVT1 has been found
to be involved in poor prognosis in colorectal cancer and gastric cancer [27,28]. In non-small cell
lung cancer, it promotes tumorigenesis [29]. In PCa, PVT1 has been found to have an increased
expression in comparison to normal prostate tissue with the presence of a newly identified functional
PCa specific genetic variant, rs378854 [30]. PVT1 encodes for several transcripts, approximately 12
exons, and their differential expression has not previously been investigated. Consequently, in the
present study, we report data on the relative expression of the 12 different exons of PVT1 in models
representative of a wide variety of clinical PCa. Our observations indicate that exon 9 of PVT1
is significantly overexpressed in PCa derived from aggressive PCa in MoAA, thus suggesting the
potential for clinical utility in this population group least served by current management strategies.
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non-tumorigenic. WPE1-NA22 cells were obtained by exposing RWPE1 to N-methyl-N-nitrosourea. 
WPE1-NA22 cells are mildly tumorigenic. MDA PCa 2b cells were derived from bone metastasis of 
prostate adenocarcinoma in a 64-year-old MoAA. PC-3 was derived from bone metastasis of a grade 
IV prostatic adenocarcinoma from a 62-year-old CM. The VCaP cell line was established from a 
vertebral bone metastasis from a 59-year-old CM with hormone refractory PCa. The E006AA cell line 
Figure 1. PVT1 localization on chromosome 8q24. PVT1 is a 300 kb long non-protein coding
gene locus found at the 8q24 human chromosomal region. The PVT1 gene locus comprises at least
12 annotated exons.
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2. Materials and Methods
2.1. Cell Lines
For this study, seven prostate epithelial cell lines were used, in representation of the
heterogeneity notable in clinical PCa. The RWPE1 cells are epithelial cells derived from the peripheral
zone of a histologically normal prostate from a 54-year-old CM. The cells were later transfected with
a single copy of the human papilloma virus 18 (HPV-18) to finally establish the cell line. RWPE1 is
non-tumorigenic. WPE1-NA22 cells were obtained by exposing RWPE1 to N-methyl-N-nitrosourea.
WPE1-NA22 cells are mildly tumorigenic. MDA PCa 2b cells were derived from bone metastasis
of prostate adenocarcinoma in a 64-year-old MoAA. PC-3 was derived from bone metastasis of a
grade IV prostatic adenocarcinoma from a 62-year-old CM. The VCaP cell line was established from
a vertebral bone metastasis from a 59-year-old CM with hormone refractory PCa. The E006AA cell
line was established in 2004 by Koochekpour et al. [31], from a 50-year-old MoAA who underwent
radical retropubic prostatectomy for treatment of clinically-localized PCa. The E006AA cell line is
non-tumorigenic in nude mice. The highly tumorigenic derivative of E006AA, the E006AA-hT cell
line, was established and characterized in 2014. The main features of all the cell lines used in this
study are summarized in Table 1.
All the cell lines were purchased from the American Type Culture Collection (ATCC, Manassas,
VA, USA) except for the E006AA and E006AA-hT cell lines that were a kind gift from Dr. Shariar
Koochekpour of the Roswell Park Cancer Institute (New York, USA).
Table 1. Main characteristics of prostate epithelial cell lines used in this study.
































2.2. Cell Culture and Cell Culture Reagents
RWPE1 and WPE1-NA22 cells were maintained in Keratinocyte-Serum Free Medium (Life
Technologies, Grand Island, NY, USA) supplemented with 0.05 mg/mL bovine pituitary extract
and 5 ng/mL human Epidermal Growth Factor. MDA PCa 2b cells were maintained in F-12K
medium supplemented with 20% fetal bovine serum (FBS), 25 ng/mL cholera toxin, 10 ng/mL
mouse epidermal growth factor, 0.005 mM phosphoethanolamine, 100 pg/mL hydrocortisone, 45 nM
selenous acid and 0.005 mg/mL bovine insulin. PC-3 cells were maintained in F-12K medium
supplemented with 10% FBS. VCaP cells were maintained in DMEM medium supplemented with
10% FBS. E006AA and E006AA-hT cells were maintained in DMEM medium supplemented with
10% FBS. All cell lines were also cultured with the presence of 1% Penicillin/Streptomycin.
2.3. Primer Design and Sequences
Prior to our study, the following PVT1 exons were described: 1a, 2, 3b, 4b, 7, 8 and 9 [13].
However, using the UCSC Genome browser, we carefully annotated the PVT1 sequence and 12 exons
were retrieved from the analysis. The Primers3 Plus software [32] was used to custom-design primers
for all 12 annotated exons, and the sequences of the primers are listed in Table 2.
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Table 2. List of primer sequences of PVT1 exons; * patent pending.
Primer Name Primer Sequence 51-31
PVT1 Exon 1A-F ACGAGCTGCGAGCAAAGA
PVT1 Exon 1A-R CGTGTCTCCACAGGTCACAG
PVT1 Exon 1B-F CGGAAGCTGCAGAAGGACAAA
PVT1 Exon 1B-R CTCAAATAATGGAGACCAGGCCA
PVT1 Exon 1C-F GCAGTGCAGGAAGCCAACTA
PVT1 Exon 1C-F CTTAGGGGTCCTTACAGCCAAG
PVT1 Exon 2-F AACCATGCACTGGAATGACA
PVT1 Exon 2-R CATCAGATGCTTCACCAGGA
PVT1 Exon 3B-F CATACTCCCTGGAGCCTTCTC
PVT1 Exon 3B-R CAGTGTCCTGGCAGTAAAAGG
PVT1 Exon 4A-F GGGTTCAAGTGATCCTCCTG
PVT1 Exon 4A-R TGTAATCCCAGCACGTTGAA
PVT1 Exon 4B-F CACCTGGGATTTAGGCACTT
PVT1 Exon 4B-R CCAATCTCAAAATACTCCAGCTTT
PVT1 Exon 5-F GCCAACAGAGATTTTGAGAAACAC
PVT1 Exon 5-R TCAGCTCAGGTTCCCATTGT
PVT1 Exon 6-F TGCTAGGGTGACAGAAACTGG
PVT1 Exon 6-R CCCAGGTCTTGATGACAGGT
PVT1 Exon 7-F TTGGTGCTCTGTGTTCACCT
PVT1 Exon 7-R TGTCCACTAGCAGCAACAGG
PVT1 Exon 8-F AGAATAACGGGCTCCCAGAT
PVT1 Exon 8-R AAGCTGGGTCTTCATCCTGA
PVT1 Exon 9-F * CATGACTCCACCTGGACCTT
PVT1 Exon 9-R * GTGGGCGATGAAGTTCGTA
2.4. RNA Extraction and RT-QPCR
At 75% confluency, total RNA was extracted from cells in a 60 ˆ 15 mm tissue culture dish,
using RNeasy Mini Kit (Qiagen, Germany, cat# 74104). After quantification with Nanodrop1000
spectrophotometer (NanoDrop, Madison, WI, USA), 1 µg of RNA was reverse-transcribed into cDNA
using QuantiTect Reverse Transcription kit (Qiagen, Germany, cat# 205311). Amplification reactions
were performed in 25 µL reaction volume using SYBR Green PCR master Mix (Life Technologies,
Grand Island, NY, USA cat# 4309155), cDNA template and 0.4 µM final concentration for primers.
The thermal cycle profile employed was as follows: 50 ˝C for 2 min, 10 min initial denaturation at
95 ˝C, and 40 cycles of 15 s denaturation at 94 ˝C, 1 min annealing at 65 ˝C. A dissociation curve
was also added at the end of the cycle. The amplifications were carried out on the 7500 Real Time
PCR machine (Applied Biosystems instruments, Grand Island, NY, USA). Messenger RNA (mRNA)
expression was assessed in quadruplicates in at least 3 independent experiments and normalized
to RPL32 mRNA expression. Relative expression levels were calculated by the Ct method (∆∆ Ct).
Previously published RPL32 primer sequences were used [31].
2.5. Statistical Analysis
Data are presented as mean ˘ standard error of the mean (S.E.M) of at least three independent
experiments. Statistical significance of differences was assessed using two-tailed Student’s t test.
p values less than 0.05 were deemed significant. A summary of all p values resulting from comparing
each prostate cell line to the normal prostate cell line RWPE1 for all PVT1 exons are summarized
in Table 3.
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Table 3. Summary of p values comparing each prostate cell line to the normal prostate cell line RWPE1
for all PVT1 exons.
PVT1 exon WPE1-NA22 MDA PCa 2b E006AA E006AA-hT PC-3 VCaP
PVT1 Exon 1A 0.4148 0.1017 0.2865 0.0262
PVT1 Exon 1B 0.2950 0.0133 0.0060 0.3158
PVT1 Exon 1C 0.2864 0.2326 0.0686 0.0369
PVT1 Exon 2 0.3284 0.0016 0.0114 0.2598
PVT1 Exon 3B 0.4073 0.4516 0.0359 0.1179
PVT1 Exon 4A 0.4410 0.0010 0.3320 0.2397 0.1518 0.0633
PVT1 Exon 4B 0.0780 0.4943 0.0130 0.4064
PVT1 Exon 5 0.1867 0.0244 0.3641 0.0938
PVT1 Exon 6 0.1160 0.4997 0.3313 0.0409
PVT1 Exon 7 0.1976 0.1799 0.3066 0.1383
PVT1 Exon 8 0.1492 0.2963 0.0255 0.0650
PVT1 Exon 9 0.0179 0.0050 0.0742 0.0416 0.0007 0.3552
3. Results
We sought to assess the expression of 12 annotated PVT1 exons in various prostate cancer cell
lines. Initial experiments focused on identifying exons that may be significantly overexpressed or
underexpressed in PCa cell lines derived from MoAA.
For PVT1 exon 1a and 1c, no significant differential expression was observed in the MDA PCa 2b
PCA cell line derived from a male of African ancestry, when compared to the RWPE1 normal prostate
epithelial cell line (Figure 2). For PVT1 exon 1b, a decrease in the expression level was observed in
the MDA PCa 2b cell line, but it was not significant (Figure 2).
For PVT1 exon 2, we observed a small but significant decrease (p value = 0.00161) in relative
expression by MDA PCa 2b in comparison to RWPE1 (Figure 3). However, for PVT1 exon 3b,
no difference in relative expression was observed when MDA PCa 2b was compared to RWPE1
(Figure 3). For PVT1 exon 4a, a significant decrease in relative expression by MDA PCa 2b of almost
60% in comparison to RWPE1 was observed (p value = 0.001104). However, PVT1 Exon 4a was
overexpressed in the highly tumorigenic E006AA-hT also derived from a MoAA (Figure 3). However,
this overexpression was not statistically significant (p value = 0.2397). Given that both MDA PCa 2b
and E006AA-hT are highly tumorigenic and derived from MoAA, the dissimilar expression of PVT1




Figure 2. PVT1 exons 1a (A); 1b (B) and 1c (C) expression in non-tumorigenic and 
tumorigenic prostate epithelial cell lines. Four independent qPCR experiments were 
performed and every experiment was set up in quadruplicates. The data showed that there 
is no significant differential expression of the exons in the cell lines in comparing cell lines 
derived from CM with those derived from MoAA. The data are presented as mean + standard 
error of the mean (SEM). 
Figure 2. Cont.
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Figure 3. PVT1 exons 2 (A); 3b (B); and 4a (C) expression in non-tumorigenic and 
tumorigenic prostate epithelial cell lines. Four (for exon 2 and exon 3b) or 3 (for exon 4a) 
independent qPCR experiments were performed and every experiment was set up in 
quadruplicates. The data showed that there is no significant differential expression of the 
exons in the cell lines in comparing cell lines derived from CM with those derived from 
MoAA. The data are presented as mean + standard error of the mean (SEM). 
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Figure 3. PVT1 exons 2 (A); 3b (B); and 4a (C) expression in non-tumorigenic and tumorigenic prostate
epithelial cell lines. Four (for exon 2 and exon 3b) or 3 (for exon 4a) independent qPCR experiments
were performed and every experiment was set up in quadruplicates. The data showed that there is no
significant differential expression of the exons in the cell lines in comparing cell lines derived from CM
with those derived from MoAA. The data are presented as mean + standard error of the mean (SEM).
For PVT1 exons 4b, 5, 6 (Figure 4), 7 and 8 (Figure 5), there were no differential expression
observed in comparing MDA PCa 2b to RWPE1.
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prostate epithelial cell lines. Four independent qPCR experiments were performed and 
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independent qPCR experiments were performed and very experiment was set up i qu druplicates.
The data showed that PVT1 exon 9 is consistently significantly overexpressed in the aggressive PCa
cell lines derived from MoAA in comparison to the non-tumorigenic PCa cell line it was derived from.
The data are presented as mean + standard error of the mean (SEM) and the p values are displayed on
the figure. The lower panel shows the different prostate cell lines’ PVT1 exon 9 PCR products loaded
on a 0.8% agarose gel.
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PVT1 exon 9 was the only one of all 12 exons of PVT1 that showed a very consistent and easily
explainable expression profile. PVT1 exon 9 was significantly and consistently overexpressed in
both aggressively tumorigenic cell lines derived from men of African ancestry. In both MDA PCa
2b and E006AA-hT cell lines, relative expression of PVT1 exon 9 in comparison to the RWPE1 cell
line were approximately 200% (two-fold) higher (Figure 6). Interestingly, in comparing the E006AA
non-tumorigenic cell line derived from a MoAA with its derivative, the aggressively tumorigenic
E006AA-hT cell line, PVT1 exon 9 expression was about 300% higher in the E006AA-hT cell line
(p = 0.0487; Figure 7). This indicates that PVT1 exon 9 is related to aggressiveness in this model of
PCa in a MoAA.
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experiment was set up in quadruplicates. The data showed that PVT1 exon 9 is consistently 
significantly overexpressed in the aggressive PCA cell lines derived from MoAA. The data 
are presented as mean + standard error of the mean (SEM) and the p values are displayed 
on the figure, and are compared to the control (RWPE1 cell line). 
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Figure 7. PVT1 exon 9 expression in non-tumorigenic and tumorigenic prostate epithelial cell lines.
At least three independent qPCR experiments were performed and every experiment was set up in
quadruplicates. The data showed that PVT1 exon 9 is consistently significantly overexpressed in the
aggressive PCA cell lines derived from MoAA. The are presented as mean + standard error of the
mean (SEM) and the p values are displayed on the figure, and are compared to the control (RWPE1
cell line).
4. Discussion
The long non-protein coding RNA (lncRNA) PVT1 has been shown to be important in cancer.
PVT1 overexpression has been demonstrated in pancreatic cancer and colon cancer, and is related to
poor prognosis in most of these cases [27–29]. However, these studies did not distinguish between
the different transcripts of PVT1. It is possible that the different exons of PVT1 could be differentially
expr ssed, and have diff rent functions. Here, we report for the first time study where we
annotated and designed primers for amplification of 12 separate exons of PVT1. Our results show
that most of the exons do not have differential expression in PCa. However, very interestingly,
one particular exon of PVT1, PVT1 exon 9, was consistently and significantly overexpressed in the
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aggressive PCa cell lines derived from MoAA. Importantly, we demonstrate that PVT1 exon 9 is
significantly overexpressed in the aggressive PCa cell line derived from a MoAA in comparison
to its non-tumorigenic cell line from which it was derived. This clearly indicates that PVT1 exon
9 overexpression is significantly associated with aggressiveness in this model of PCa in a MoAA.
Whether this will translate to individuals or subpopulations at risk prospectively is at present
unknown. A more in depth evaluation of prospectively collected PCa gene databases and fresh
prostate specimens will be required to understand whether this phenomenon can be used as a
biomarker for MoAA with PCa.
To determine if a lncRNA is important, its cellular functions need to be elucidated. It will be
important to determine if the lncRNA regulates important cellular functions or if it just represents
“transcriptional noise” or background transcription. Although lncRNAs are sometimes aberrantly
expressed in diseased tissues, suggesting specific functions in diseases, our knowledge of how these
lncRNA act in the cell and which roles they might play in diseases in still very limited [32,33].
Therefore, an understanding of the cellular functions, mechanisms of action, and mechanisms
regulating PVT1 exon 9 expression will be critical to exploiting it for potential clinical applications.
Our results show that PVT1 exon 9 is consistently overexpressed in aggressively tumorigenic
PCa cell lines derived from MoAA. This observed overexpression of PVT1 exon 9 in the aggressive
PCa cell lines derived from MoAA suggests that PVT1 exon 9 may contribute to the high proportion
of PCa aggressiveness in MoAA. To better understand the cellular and molecular mechanisms of
this contribution, we need to understand the functional role of PVT1 exon 9 in PCa development
and progression. To this end, its expression pattern in human PCa with varied clinico-pathological
characteristics, its cellular functions, its molecular mechanisms of action, and its molecular targets
will need to be determined. Some of this work has started to be done in other cancers. For example,
in 2014, Takahashi et al. reported that the amplification of PVT1 was involved in poor prognosis via
the inhibition of apoptosis in colon cancers [27].
Assessing for a functional role for PVT1 exon 9 could be done by studying the effects of silencing
of PVT1 transcripts using the RNAi approach. In this regard, Gray and colleagues were able to induce
apoptosis in ovarian or breast cancer cell lines by silencing of PVT1 in cell lines with amplified
chr.8q24 but they found no apoptosis in non-amplified cell lines [34]. Similar studies assessing
cellular function will need to be performed in PCa. Understanding the role of PVT1 exon 9 in PCa
aggressiveness in MoAA may lead to the future possibility of exploiting PVT1 exon 9 for diagnosis,
therapy, and other clinical applications in PCa.
5. Conclusions
The present study reports the overexpression of PVT1 exon 9 by aggressively tumorigenic PCa
cell lines derived from MoAA. Based on this consistent overexpression of PVT1 exon 9 by aggressive
PCa cell lines derived from MoAA, it is possible that PVT1 exon 9 is important and may contribute to
the disproportionately increased aggressiveness of PCa in MoAA.
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